london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Intravitreal dexamethasone implant for DME unresponsive to prior treatments

Poster Details

First Author: G.Gulkilik TURKEY

Co Author(s):    G. Demirci   S. Karaman   M. Ozbek   M. Odabasi   M. Ozsutcu   S. Kocabora   0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the efficacy and safety of intravitreal dexamethasone implant for diffuse diabetic macular edema unresponsive to prior treatments.

Setting:

Istanbul Medipol University Department Of Ophthalmology, Istanbul, TURKEY

Methods:

In this retrospective interventional case series 4 eyes of 3 subjects with diffuse diabetic macular edema unresponsive to laser photocoagulation and intravitreal antiVEGF treatment received a single intravitreal injection of 0.7 mg dexamethasone implant (Ozurdex®; Allergan Inc, Irvine, CA, USA). Main outcome measures were change in best corrected visual acuity (BCVA) and central macular thickness (CMT) as measured by spectral domain optical coherence tomography (SD-OCT). Change in intraocular pressure (IOP) was also evaluated.

Results:

Patient 1; Prior to dexamethasone implant, BCVA was counting fingers at 1 meter in both eyes and CMT was 772 µm and 716µm in the right and left eyes respectively. One month after treatment BCVA improved to 0.1 in both eyes and CMT decreased to 279 µm and 299 µm in the right and left eyes. CMT further decreased and BCVA was stable for 4 months . At month 6 BCVA decreased to 0.05 in both eyes and edema recurred with CMT of 601 µm and 891 µm Patient 2; Baseline BCVA was 0.2 with a CMT of 545 µm in the right eye. One month after injection BCVA improved to 0.6 and CMT decreased to 281 µm. This improvement was stable for 4 months in which BCVA decreased to 0.4 and edema recurred with a CMT of 468 µm. Patient 3; Baseline BCVA was 0.05 with a CMT of 619 µm in ht eright eye. One month after dexamethasone implant BCVA improved to 0.2and CMT was measured as 339 µm. Both BCVA and CMT remained stable for 4 months. . IOP did not increase in any eyes above 20mmHg throughout the follow up.

Conclusions:

Dexamethasone intravitreal implant (Ozurdex®) was effective and safe in the treatment of diffuse diabetic macular edema unresponsive to other treatments. Its duration of effect was limited around 4 to 5 months. Further controlled studies with large number of patients are required to confirm the efficacy and safety of this treatment.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy